Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NEXTCURE INC (NXTC) Stock Price & Overview
NASDAQ:NXTC • US65343E2072
Current stock price
9.36 USD
+0.15 (+1.63%)
Last:
The current stock price of NXTC is 9.36 USD. Today NXTC is up by 1.63%. In the past month the price decreased by -12.69%. In the past year, price increased by 76.27%.
NXTC Key Statistics
52-Week Range4.0944 - 15.7399
Current NXTC stock price positioned within its 52-week range.
1-Month Range8.5201 - 13.5
Current NXTC stock price positioned within its 1-month range.
- Market Cap
- 33.322M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.00
- Dividend Yield
- N/A
NXTC Stock Performance
Today
+1.63%
1 Week
-11.03%
1 Month
-12.69%
3 Months
-13.73%
Longer-term
6 Months -25.71%
1 Year +76.27%
2 Years -49.35%
3 Years -54.65%
5 Years -90.06%
10 Years N/A
NXTC Stock Chart
NXTC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NXTC. When comparing the yearly performance of all stocks, NXTC is one of the better performing stocks in the market, outperforming 84.04% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NXTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NXTC. NXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NXTC Earnings
Next Earnings DateAug 5, 2026
Last Earnings DateApr 29, 2026
PeriodQ4 / 2025
EPS Reported-$0.81
Revenue Reported
EPS Surprise 67.14%
Revenue Surprise %
NXTC Forecast & Estimates
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 92.52% is expected in the next year compared to the current price of 9.36.
Analysts
Analysts84.44
Price Target18.02 (92.52%)
EPS Next Y58.54%
Revenue Next YearN/A
NXTC Financial Highlights
Over the last trailing twelve months NXTC reported a non-GAAP Earnings per Share(EPS) of -20. The EPS increased by 15.82% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-55.84M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.28% | ||
| ROE | -159.81% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%83.54%
Sales Q2Q%N/A
EPS 1Y (TTM)15.82%
Revenue 1Y (TTM)N/A
NXTC Ownership
Ownership
Inst Owners49.08%
Shares3.56M
Float3.02M
Ins Owners1.15%
Short Float %2.38%
Short Ratio1.41
NXTC Industry Overview
NXTC operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
NXTC Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NXTC
Company Profile
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Company Info
IPO: 2019-05-09
NEXTCURE INC
9000 Virginia Manor Rd Ste 200
Beltsville MARYLAND 20705 US
CEO: Michael Richman
Employees: 40
Phone: 12403994900
NEXTCURE INC / NXTC FAQ
What does NEXTCURE INC do?
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
What is the stock price of NEXTCURE INC today?
The current stock price of NXTC is 9.36 USD. The price increased by 1.63% in the last trading session.
What is the dividend status of NEXTCURE INC?
NXTC does not pay a dividend.
What is the ChartMill rating of NEXTCURE INC stock?
NXTC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for NXTC stock?
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 92.52% is expected in the next year compared to the current price of 9.36.
Would investing in NEXTCURE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NXTC.
Can you provide the number of employees for NEXTCURE INC?
NEXTCURE INC (NXTC) currently has 40 employees.